UNSPSC 51281708: Sultamicillin

This classification denotes an anti-bacterial agent and ampicillin with the molecular formula C25H30N4O9S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65DT0ML581, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (((3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-yl)carbonyl)oxy)methyl ester, s,s-dioxide, (2s-(2alpha(2r*,5s*),5alpha,6beta(s*)))- but generally known as sultamicillin, which bears US NIH Compound Identifier 53512.

UNSPSC 51281708 Sultamicillin is a Commodity code that nominally describes a specific antibiotic pharmaceutical product, yet recent state and local procurement activity under this code shows minimal relevant purchasing. The two opportunities tagged to the code involve naloxone kits and safe drug deactivation systems (Seminole County, Florida) and doxycycline and ciprofloxacin tablets through a pharmaceutical piggyback contract (Illinois Department of Public Health), neither of which align with sultamicillin procurement. State and local buyers—including county health departments and state health agencies—do use this taxonomy tier for pharmaceutical commodities, but the recent record does not demonstrate active or sustained buying of sultamicillin itself under this specific code.

Geographic activity appears limited to Florida and Illinois based on the tagged records, though the mismatch between the code's nominal scope and the actual products being procured suggests the code may see little state and local use or that jurisdictions are applying it inconsistently. The Illinois Department of Public Health awarded a $2,999,999.11 three-year pharmaceutical warehouse piggyback contract to Chartwell Rx LLC through the MMCAP Infuse consortium (Bid Number 26-482DPH-PREPD-B-53392) for antibiotic tablets, and Seminole County issued an IFB for naloxone and drug deactivation systems with a July 26, 2023 response deadline. Neither opportunity directly targets sultamicillin, indicating the code warrants close monitoring but shows no actionable current demand for firms specializing in this particular pharmaceutical.